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ABSTRACT 
Retinal ischemic diseases like retinopathy of prematurity (ROP), diabetic retinopathy 
(DRP) and retinal vein occlusion, with preretinal neovascularization (angiogenesis) that 
may lead to vitreous hemorrhages and retinal detachment with subsequent vision loss 
and blindness is a global health problem.  
 
By analyzing the potential role of molecules acting at different levels of the angiogenic 
cascade the presented studies aimed to widen our understanding of retinal ischemic 
diseases on a molecular, cellular and morphologic level. All studies were based on an 
experimental model of oxygen-induced retinopathy (OIR) where neonatal mice 
exposed to a hyperoxic environment develop pathologic retinal neovascularization. 
Genetically modified mice lacking functional genes (so called knock-out mice (KO)) 
for matrix metalloproteinase-2 (MMP-2), the adenosine A2A receptor (A2AR) or 
interleukin-10 (IL-10) were studied. In addition, purinergic P2 receptors were 
investigated in normal mice. Retinal neovascularization was quantified by counting 
neovascular nuclei in retinal cross-sections. Retinal vessel development and capillary 
free areas were investigated by fluorescein staining of retinal flatmounts. P2 receptor 
expression and studies of the inflammatory reaction were performed with 
immunohistochemistry. In situ hybridization and real time-Polymerase Chain Reaction 
(rt-PCR) were used for identification of mRNA of relevant target molecules. 
In the first study MMP-2, a member of an enzyme family essential for degradation of 
extracellular matrix (ECM) and the vascular basement membrane was not found to 
interfere with normal retinal vessel development. In OIR there was increased retinal 
neovascularization in the MMP-2 KO mice pointing at MMP-2 having an anti-
angiogenic effect in this model.  
In the second study, the expression of P2X2 and P2Y2 receptors were found to be up-
regulated by oxygen exposure. Retinal neovascularization was strongly inhibited by the 
P2 antagonists suramin and PPADS and this was accompanied with a down-regulation 
of P2X2 receptor expression suggesting a role for P2 receptors in OIR.  
In the third study, hyperoxia was seen to reduce A2AR mRNA expression but the 
decline in receptor expression between postnatal day 12 (P12) and P17 seen in control 
animals was absent in retinas exposed to hyperoxia. The area of vascular regression 
was smaller in A2AR KO mice and there was also reduced retinal neovascularization. 
Gene microarray expression analyses of retinas of hyperoxia-treated mice showed that 
the P12 wild-type (WT) mice differed considerably from the P12 A2AR KO mice and at 
all other time-points. The results thus show that the A2AR exacerbates the initial 
vasoobliterative phase in OIR. 
In the fourth study, the anti-inflammatory cytokine IL-10 was found to act as a pro-
angiogenic factor in the OIR model and occasional macrophages/microglial cells were 
seen in WT mice.  
In conclusion, the presented work has, in different ways, tried to enlighten the complex 
process of retinal angiogenesis and has identified some potential strategies for treatment 
of  neovascular retinopathies including inhibition of P2 receptor and A2AR signaling. 
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LIST OF ABBREVIATIONS 
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TIMPs Tissue inhibitors of metalloproteinases 
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VEGF Vascular endothelial growth factor 
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1 INTRODUCTION 
1.1 THE RETINA 
The retina is the innermost coat of the eyewall extending from the optic nerve to the ora 
serrata in the retinal periphery. It is composed of the outer retinal pigment epithelium 
(RPE) and the inner neural retina facing the choroid and the corpus vitreum 
respectively. The inner 2/3 of the retina receives its blood supply through the retinal 
circulation. The outer 1/3 of the retina instead is supplied through the choroidal 
circulation. The retina has several layers. From the inner to outer retina the layers they 
are: 1) the internal limiting membrane (ILM), 2) the nerve fiber layer (NFL), 3) the 
ganglion cell layer (GCL), 4) the inner plexiform layer (IPL), 5) the inner nuclear layer 
(INL), 6) the outer plexiform layer (OPL), 7) the outer nuclear layer (the nuclei of the 
photoreceptors, ONL), 8) the external limiting membrane, 9) the rod and cone inner 
and outer segments, and 10) the retinal pigment epithelium (RPE). 
 
 
 
 
 
 
 
1.2 VASCULAR DEVELOPMENT 
At the third week during embryonal development mesoderm cells differentiate into 
blood cells and blood vessels. These cells, known as angioblasts, form isolated clusters 
and cords, which gradually become canalized. By endothelial cell sprouting and after 
fusion they give rise to small blood vessels and a capillary network. (Langman 1980). 
This de novo formation of blood vessels from precursor cells is called vasculogenesis 
(Penn 2008). Vasculogenesis can also occur in the adult organism from circulating 
endothelial progenitor cells (derivatives of stem cells) able to contribute, to varying 
degrees, to neovascularization. Examples of vasculogenesis in adults are during tumor 
growth (Gao 2008), revascularization following trauma, e.g., after cardiac ischemia 
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(Asahara 1999) and in endometriosis (Laschke 2011). The formation of new capillaries 
and blood vessels from pre-existing ones is called angiogenesis (Carmeliet 2011). It is 
mainly driven by hypoxia. It occurs physiologically during endometrial growth as part 
of the menstrual cycle, in wound healing and in ischemic lesions in the heart and brain. 
It also occurs pathologically in tumour growth and in ischemic retinopathies in the eye. 
  
 
1.3 ANGIOGENESIS 
The field of angiogenesis has evolved rapidly since its discovery some forty years ago. 
In 1971, Judah Folkman hypothesized that angiogenesis was a process vital for 
malignant tumor growth in cancer (Folkman 1971) and in 1989 Napoleone Ferrara and 
coworkers made ground-breaking discoveries identifying and isolating vascular 
endothelial growth factor (VEGF) as the main growth factor in vessel development 
(Leung 1989). Further research has revealed that angiogenesis is a complex, multistep, 
process involving several growth factors, matrix metalloproteinases (MMP) and 
cytokines. 
 
1.3.1 The angiogenic cascade 
When an angiogenic signal, such as VEGF expression from hypoxic tissue, is received 
by an existing, quiescent, vessel the basement membrane surrounding the vessel has to 
be disrupted and the pericytes, become detached from the vessel wall. Also the 
adhesive function of the junction molecule vascular endothelial cadherin (VE-cadherin) 
between adjacent endothelial cells is internalised in response to VEGF (Carmeliet 
2011). The surrounding extracellular matrix (ECM) needs to be partially degraded to 
facilitate the cellular infiltration. This proteolytic degradation is mediated by MMPs. As 
VEGF increases the permeability of the endothelial cell layer in the vessel wall, plasma 
proteins extravasate and form a new ECM scaffold. Endothelial cells migrate onto this 
ECM surface. From the original vessel, upon stimulation by VEGF, a leading 
endothelial cell, “tip cell”, is chosen to lead the growth of the new vessel supported by 
neighboring endothelial, “stalk cells”. Tip cells have filopodia to sense environmental 
guidance and grow along a gradient of VEGF (Gerhardt 2003). The tip cell also 
expresses MMP activity for digesting the surrounding ECM. Later during angiogenesis, 
when the stalk cells get into contact with pericytes, the endothelial cells down-regulate 
MMP again. After fusion of neighboring branches the endothelial cell cords are 
transformed into tubes by the formation of vacuoles within the endothelial cells. To 
properly seal the new vessels, VE-cadherin-mediated junctions between endothelial 
cells are reformed (Carmeliet 2011).. Structural support is provided by the deposition of 
a basement membrane around the new vessel assisted by the release of MMP inhibitors 
(tissue inhibitors of metalloproteinases (TIMPs)). Thereafter, recruitment of pericytes is 
initated by platelet derived growth factor-B (PDGF-B), an association essential for 
maturation of the endothelial cell tubes into blood vessels. This process is also 
supported by the binding of the angiopoetin-1 (Ang-1) to its receptor tyrosine kinase 
with immunoglobulin (Ig)-like and epidermal growth factor (EGF) homology domains 
2 (Tie2) and enables a tight endothelial cell-pericyte interaction and further vessel 
stabilization. Vascular maturation promotes vessel integrity and inhibition of vascular 
leakage. The onset of blood flow and improved oxygen delivery lowers local VEGF 
production. The immature capillary plexus is early on excessively branched and have 
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an abundance of tubes. At this stage of angiogenesis, changes in the local balance of 
pro- and anti-angiogenic factors may lead to the elimination (pruning) of the new 
capillaries; for example by endothelial cell apoptosis. The pruning process is most 
extensive around the oxygen-rich arteries in the developing retina (Eble 2009, Adams 
2007, Carmeliet 2011).    
 
1.3.2 Pro- and anti-angiogenic factors 
VEGF binds to two related receptor tyrosinase kinases, VEGFR-1(Flt-1) and VEGFR-2 
(KDR). These receptors are expressed on the cell surface of most vascular endothelial 
cells, monocytes, macrophages and hematopoietic stem cells. VEGFR-2 is the major 
mediator of the mitogenic, angiogenic and permeability enhancing effects of VEGF. 
VEGFR-1 is not directly involved in mitogenesis and angiogenesis. It may, under some 
circumstances, function as a “decoy” receptor that sequesters VEGF and prevents its 
interaction with VEGFR-2 (Ferrara 2004). 
 
Platelet-derived growth factor-B (PDGF-B) is expressed by endothelial cells and by 
pericytes (Potente 2011). PDGF-B and its receptor (PDGFR-β) are essential for the 
recruitment of mural cells and for the stabilization of nascent blood vessels via 
coverage with pericytes in the later stages of the angiogenic cascade (Carmeliet 2004).  
 
The Ang–Tie receptor system is an important receptor regulatory signaling system 
along the VEGF–VEGFR receptor system. The Ang family are protein growth factors 
that promote angiogenesis. There are four identified Ang: Ang1, Ang2, Ang3 and 
Ang4. Ang-1 and Ang-2 are antagonistic ligands that bind to the extracellular domain 
of the Tie2 receptor. Binding of Ang-1 to Tie2 causes tight endothelial cell-pericyte 
interaction and vessel stabilization promoting vessel integrity that inhibits vascular 
leakage. Ang-1 and VEGF control vascular maturation by recruiting mural cells to the 
endothelial plexus. As a result of pericyte-endothelial interaction, mature vessels lose 
their dependence on VEGF, and thus the plasticity window is closed (Augustin 2009, 
Singh 2011). 
  
1.3.3 Proteolysis of the basement membrane 
MMPs are a family of over 20 zink-containing enzymes capable of degrading different 
components of the ECM. They are produced as latent, pro-enzymes, which must be 
proteolytically processed to be activated. Endothelial cells produce many of the MMPs. 
MMPs are divided into five subgroups based on their structure and/or substrate 
specificities. These are the matrilysins (MMP-7 and MMP-26), the collagenases 
(MMP-1, MMP-8, MMP-13), the stromelysins (MMP-3, MMP-10, MMP-12), the 
gelatinases (MMP-2, MMP-9) and the membrane-type MMPs (MMP-14, MMP-15, 
MMP-16, MMP-24). The gelatinases have a preference for denatured collagens 
(gelatin) and also degrade types IV, V, VII and X native fibronectin and laminin. 
During angiogenesis MMPs are essential for the degradation of the vascular basement 
membrane and remodeling of the ECM in order to allow endothelial cells to migrate 
and invade the surrounding tissue. In addition, the MMPs assist in detaching pericytes 
from the vessels undergoing angiogenesis, release ECM-bound angiogenic growth 
factors (Hashimoto 2002), expose cryptic epitopes in ECM proteins and cleave 
endothelial cell-cell adhesions. MMP activity is regulated by TIMPs in tissues whereas 
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in plasma, the main protease inhibitor, α2-makroglobulin, is also the predominant 
MMP inhibitor. The MMPs also have an anti-angiogenic role by generating 
endogenous angiogenesis inhibitors (eg. endostatin and tumstatin) through cleavage of 
collagen chains. MMP-2, MMP-7, MMP-9 and MMP-12 also have the capacity to 
hydrolyze plasminogen into the potent angiogenesis inhibitor angiostatin (O’Reilley 
1999) (Rundhaug 2005). Retinal neovascularization was reduced by an inhibitor of 
MMPs in the murine oxygen-induced retinopathy model (OIR) (Das 1999). Although 
preclinical studies testing the efficacy of MMP suppression in tumor models were 
encouraging, the results of clinical trials in cancer patients have been disappointing 
(Hua 2011).  
  
 
1.4 INTERLEUKIN-10 
Cytokines are a large and diverse family of small intercellular communication proteins 
secreted by numerous cells. Cytokines are grouped into lymphokines, interleukins, and 
chemokines, based on their presumed function, cell of secretion, or target of action. The 
term interleukin was initially used for those cytokines whose presumed targets are 
principally leukocytes. It is now used largely for designation of newer cytokines and 
bears little relation to their presumed function. The vast majority of interleukins are 
produced by T-helper cells. The term chemokine refers to a specific class of cytokines 
that mediates chemoattraction (chemotaxis) between cells. Cytokines, including 
chemokines and interleukins, also affect angiogenesis. Chemokines recruit leukocytes 
to ischemic tissues such as hypoxic regions in tumors, dermal wounds, atherosclerotic 
plaques, arthritic joints and in proliferative retinopathy, where the leukocytes release 
angiogenic factors in an attempt to re-establish tissue oxygenation (Lewis 1999). But, 
leukocytes can also produce angiogenesis inhibitors, making their role in initiating or 
terminating angiogenesis dependent on the temporospatial balance of these modulators 
(Carmeliet 2004). Interleukin-10 (IL-10) is an anti-inflammatory cytokine that also may 
be involved in angiogenesis. In a tumor model for melanoma and in hind-limb 
ischemia, IL-10 has anti-angiogenic properties through down-regulation of VEGF 
(Huang 1999, Silvestre 2000). But IL-10 also has pro-angiogenic properties by 
polarizing the macrophage genetic profile towards a pro-angiogenic phenotype in the 
mouse OIR model (Dace 2008). Likewise, in a model of corneal neovascularization, 
IL-10 appeared to have a pro-angiogenic effect (Samolov 2010).  
 
 
1.5 PURINERGIC SIGNALING 
The finding  of adenosintriphosphat (ATP) as a purinergic neurotransmitter in 
nonadrenergic, noncholinergic nerves in the gut and bladder was a landmark discovery 
(Burnstock 1972). Since then purinergic signaling has become an extensive field of 
research. Purines and pyrimidines have major roles in the activities of non-neuronal 
cells as well as neurons. This includes acting as co-transmitters and neuromodulators in 
most, if not all, nerve types in the peripheral and central nervous systems, platelet 
aggregation and vascular endothelial cell-mediated vasodilation (Burnstock 2002). 
More recently, purinergic signaling has been implicated in cell proliferation, migration, 
differentiation and death in embryological development, wound healing, restenosis, 
atherosclerosis, ischaemia, inflammation, neuroprotection and cancer (Burnstock 
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2006). Purinergic receptors are of two kinds, P1 (adenosine) and P2 (nucleotide). 
Adenosine receptors are subdivided into four subtypes: A1, A2A, A2B and A3, all of 
which couple to guanine nucleotide-binding proteins (G proteins). P2 receptors 
comprise two types of receptors, P2X and P2Y. The P2X family encompasses seven 
ligand-gated ion channel receptors and the P2Y family comprises eight G protein-
coupled receptors. In the retina, P1 and P2 receptors are expressed by photoreceptors, 
most neurons, glial cells, the microvasculature and by the RPE (Housley 2009). 
Adenosine induces retinal hyperemia after ischemia by increasing retinal blood flow 
through relaxation of pericytes (Ostwald 1997, Li 2001). Adenosine also serves to 
maintain tissue oxygenation in response to chronic ischemic stress by stimulating 
angiogenesis (Adair 2005). Adenosine released from hypoxic tissues activates A2 
receptors, which stimulate the release of VEGF from parenchymal cells. VEGF 
thereafter binds to VEGFR-2 on endothelial cells, stimulating their proliferation and 
migration (Adair 2005). 
P2 receptors have been proposed to have a role in retinal development (Sugioka 1999) 
and in retinal disease, including retinal detachment (Iandiev 2006), diabetic retinopathy, 
(Sugiyama 2004) and retinal degeneration (Francke 2005). 
 
 
1.6 RETINAL VASCULAR DEVELOPMENT 
In mammals, retinal vascularization begins at the optic nerve head and radiates 
outwards to the ora serrata in the retinal periphery,. In humans the retinal circulation 
begins to develop at the fourth month of gestation. At that time small branches from the 
hyaloid artery form the central retinal artery. By the eight-month of gestation, the 
retinal vessels extend to the ora serrata nasally, but only to the equator temporally. It is 
not until birth that the temporal vessels reach the ora serrata (Paysse 2011). In mice 
there are no, or only very small vessels around the optic nerve, at birth (Gyllensten 
1954). The mouse retina is therefore an ideal structure to study the vascular 
development using retinal flat-mount preparations. The primary vessel plexus at the 
inner retinal surface subsequently remodels into three parallel but inter-connected 
networks, located in the nerve fiber layer and the plexiform layers. The superficial 
vascular plexus forms during the first week after birth by radial outgrowth of vessels 
from the optic nerve into the periphery, reaching the retinal edges at approximately P8 
(postnatal day 8). From P7 onward the superficial capillaries start sprouting vertically 
to form first the deep and then the intermediate vascular plexus. The deep plexus, 
located in the outer plexiform layer, forms rapidly and reaches the retinal periphery at 
approximately P12, followed by the intermediate plexus in the inner plexiform layer 
between P12 and P15. By the end of the third postnatal week, all three vascular layers 
are fully mature with multiple interconnecting vessels between the layers (Connolly 
1988, Stahl 2010). Development of the retinal vasculature is preceded by an invasion of 
migrating astrocytes into the retina (Stone 1987, Watanabe 1988). The astrocytes form 
a cellular network that provides a template for the growing blood vessels (Ling 1988, 
Fruttiger 1996). Before the astrocytes are covered with blood vessels they experience 
hypoxia that induces VEGF expression that in turn stimulates angiogenesis (Pierce EA 
1996, West 2005). As the expanding vessel network grows over the retinal astrocytes, 
they differentiate into a more mature phenotype. Proliferation of astrocytes ceases and 
VEGF is down-regulated (West 2005). The first vascular plexus is dense and uniform.  
Over time this primitive plexus is re-modeled into a mature, hierarchical, vascular tree. 
Pruning is particularly evident in the vicinity of arteries where capillary free zones 
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emerge. This can occur via migration and re-localization of endothelial cells (Hughes 
2000) or via selective endothelial cell apoptosis (Ishida 2003).   
 
 
1.7  ROP AS A MODEL FOR RETINAL NEOVASCULARIZATION 
Retinopathy of prematurity (ROP) is a major cause of blindness in children in the 
developing and developed world. The condition was earlier known as retrolental 
fibroplasia, and was originally described in the 1940s by Terry who first connected the 
condition with premature birth (Terry 1944). Excessive oxygen use was early identified 
as a risk factor for ROP (Ashton 1954). Besides oxygen, gestational age and birth 
weight are the major risk factors for ROP (Lutty 2006). In a Swedish study of preterm 
infants born before 27 weeks' gestation, the incidence of ROP was 73% among those 
children surviving until their first eye examination. The risk of ROP was reduced by 
50% for each week of increase in gestational age at birth (Austeng 2009). ROP is a 
biphasic disease consisting of an initial phase of vessel loss followed by a second phase 
of vessel proliferation. In humans retinal blood vessel development is initiated during 
the fourth month of gestation and reaches the retinal periphery just before birth (Roth 
1977). Infants born prematurely have incompletely vascularized retinas with a 
peripheral avascular zone. The gestational age at birth of the premature infant 
determines the area of the avascular zone (Chen 2007). In premature infants vascular 
growth that would normally occur in utero slows or ceases and is accompanied by 
regression of developed retinal vessels. The relative hyperoxia of the extra-uterine 
environment as well as supplemental oxygen given to premature infants are thought to 
be responsible for this process. As the infant matures, the non-vascularized retina 
becomes increasingly metabolically active and, in the absence of an adequate vascular 
system, leads to tissue hypoxia (Chen 2007). The second phase of ROP is characterized 
by hypoxia-induced retinal neovascularization. In animal models it is shown that during 
the first, hyperoxic, phase of ROP retinal VEGF expression is significantly suppressed, 
contributing to vessel loss (Alon 1995, Pierce 1996, Gao 2002). During the second, 
hypoxic, phase however, VEGF becomes up regulated in the inner retina (Ozaki 1999) 
contributing to pathologic neovascularization (Alon 1995, Pierce 1995, Stone 1996, 
Geisen 2008). Animal studies have also shown beneficial effects of anti-VEGF 
treatment on hypoxia-driven retinal neovascularization (Aiello 1995, Robinson 1996, 
Ozaki 2000, Bainbridge 2002). In a patient with ROP, VEGF was found in the retina in 
a pattern consistent with the results in mice (Young 1997). Established treatments for 
ROP are cryotherapy and laser photocoagulation of the avascular retina and surgical 
treatment in the late stage of the disease. Recently intravitreal injection of an anti-
VEGF antibody (bevacizumab (Avastin®)) has been used with excellent result in 
severe ROP (Mintz-Hittner 2011). Uncertainties exist however with respect to dosing, 
frequency, timing and adjunct therapies. Careful attention must also be given to the 
potential for systemic complications and long-term effects in infants. The second phase 
of  ROP has common features of neovascularization in other proliferative retinopathies 
such as advanced diabetic retinopathy (DRP). Despite cryotherapy or laser 
photocoagulation of the avascular retina and surgical treatment in the late stage of the 
disease visual acuity in advanced ROP often remain poor. 
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1.8 OTHER DISEASES WITH PATHOLOGIC RETINAL 
NEOVASCULARIZATION 
DRP is a major complication in diabetes and remains a leading cause of blindness in 
the working population of developed countries. Nearly all patients with type 1 diabetes 
will develop some manifestation whereas in type 2 diabetic patients 80% of insulin-
dependent patients and 50% of patients not requiring insulin therapy will have DRP 
within 20 to 25 years following disease onset (Curtis 2009). The incidence of diabetes 
throughout the world is projected to be approximately 300 million by the year 2025 
(Curtis 2009). Proliferative DRP occurs in approximately 50% of patients with type I 
diabetes and in about 15% of patients with type II diabetes with disease for 25 years 
(Klein 1984a, Klein 1984b). Thickening of the capillary basement membrane, pericyte 
and smooth muscle cell dropout, microaneurysms and capillary occlusion all lead to 
tissue ischemia and eventually retinal neovascularization. Retinal vein occlusions, 
sickle-cell anemia and other vascular obliterating diseases also lead to tissue hypoxia 
and pathologic retinal neovascularization. Intraocular VEGF levels are significantly 
higher in patients with active retinal neovascularization including proliferative DRP 
and ischemic central retinal vein occlusion than in patients with no proliferative 
disorder (Aiello 1994). VEGF has also been demonstrated in ocular membranes from 
patients with proliferative DRP (Malecaze 1994). 
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2 AIMS OF THE PROJECT 
 
To analyze the potential role of molecules acting at different levels of the angiogenic 
cascade in experimental retinal neovascularization and in normal retinal development 
 
Specifically I wanted to: 
 
Study the expression and role of MMP-2 in experimental retinal neovascularization and 
in normal retinal development 
 
Study the expression and role of P2 receptors in experimental retinal neovascularization 
 
Study the expression and role of A2AR in experimental retinal neovascularization 
 
Study the role of the anti-inflammatory cytokine IL-10 in experimental retinal 
neovascularization 
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3 MATERIAL AND METHODS 
3.1 LABORATORY MICE, KNOCK-OUT MICE 
Study I: MMP-2 wild-type (WT) and knockout (KO) mice, 0-19 days old, were used 
throughout the study. The generation of MMP-2 KO mice has previously been 
described (Itoh 1997) 
 
Study II: Normal C57BL/6J mice, 7-17 days old, were used throughout the study. 
 
Study III: Normal C57BL/6J and A2AR WT and KO mice, 7-17 days old were used 
throughout the study. The generation of A2AR KO mice has previously been described 
(Chen 1999). 
 
Study IV: C57BL/6J and IL-10 KO mice, 7-17 days old, were used throughout the 
study. The generation of IL-10 KO mice has previously been described (Kühn 1993).  
 
All the animals were treated in accordance with the Association for Research in Vision 
and Ophthalmology’s (ARVO´s) Statement for the Use of Animals in Ophthalmic and 
Vision Research. 
 
 
3.2 EXPERIMENTAL MODEL OF RETINAL ANGIOGENESIS 
OIR in the mouse is the experimental model of retinal angiogenesis used in all the 
present studies. It was first described in 1994 and has since become the most popular 
model to study abnormal angiogenesis in the retina (Smith 1994). It is referred to in the 
literature under several names including OIR, ischemia-induced retinopathy and 
pathologic retinal neovascularization model. In this thesis I have chosen to use the term 
OIR throughout. Many animals such as mice, rats, kittens, and beagle pups have 
incompletely vascularized retinas at birth and resemble the immature retinal vascular 
development of premature infants. However the murine model used herein has become 
the model of choice because it is reproducible and since it is easily quantifiable 
(Connor 2009, Aguilar 2008). Furthermore, the study of molecular mechanisms 
involved is greatly facilitated by the genetic tools available in mice. Mice were chosen 
at P7 since the vascular development of P7 retinas closely resembles that of premature 
infants including maximal hyaloid vascular regression and minimal retinal vascular 
development. Neonatal mice are thus exposed to 75% oxygen from P7 until P12. 
During this period of hyperoxia, vessel regression and the cessation of normal radial 
vessel growth occurs mimicking the first phase of ROP. The extent of vaso-obliteration 
can be determined by measuring the non-perfused area in retinal whole mounts. Upon 
return to room air, the non-perfused portions of the retina become hypoxic, thereby 
inducing the expression of angiogenic factors leading to retinal neovascularization. The 
neovascular phase is similar to the second phase of ROP in humans and, in addition, 
mimics certain aspects of proliferative DRP (Chen 2007). The formation of vascular 
tufts are measured by quantifying neovascular nuclei extending into the vitreous in 
cross sections of retina, or by quantifying the area of vascular tufts in retinal whole 
mounts. 
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3.3 RETINAL FLATMOUNTS 
Study I: Mice were infused with fluoresceinisothiocyanate-dextran in the left cardiac 
ventricle. Eyes were enucleated at P0, P3, P6, P9, and P15 and fixed in 
paraformaldehyde. Dissected retinas were a flatmounted and examined by fluorescence 
microscopy. The distance from the center of the optic nerve to the leading front of 
developing vascular plexus in each quadrant was measured. The mean for each 
individual was used as a single experimental value.  
 
 
3.4 IN-SITU HYBRIDIZATION 
Study I: In situ hybridization was performed on P1 to P19 formaldehyde-fixed, serial 
sections using radiolabelled T3 and T7 ribonucleic acid (RNA) polymerase–derived 
sense and antisense complementary RNA probes to MMP-2 (Kvanta 2000). After 
development, the sections were studied by light and dark-field microscopy.   
 
 
3.5 REAL TIME-POLYMERASE CHAIN REACTION (RT-PCR) 
Study I: rt-PCR was performed P12 to P19 in MMP-2 WT mice exposed or not 
exposed to hyperoxia. Total RNA was extracted from retinas and reverse transcribed to 
cDNA. Primers were used for GADPH and MMP-2 (Kuzuya 2003).  
 
Study III: rt-PCR was performed P12 to P17 in C57BL/6J mice exposed or not exposed 
to hyperoxia. Total RNA was extracted from retinas and revere transcribed to cDNA. 
Primers were used for GADPH and A2AR and A2BR (Chunn 2001). Rt-PCR was also 
performed P7 to P17 in A2AR WT and A2AR KO mice exposed to hyperoxia. Primers 
were used for GADPH and Pttg1. 
 
Study IV: rt-PCR was performed P7 to P17 in IL-10 WT mice exposed or not exposed 
to hyperoxia. Total RNA was extracted from retinas and reverse transcribed to cDNA. 
Primes were used for GADPH and IL-10. Rt-PCR was also performed in IL-10 WT 
and  KO mice exposed to hyperoxia. Primers were used for GADPH, MMP-2, MMP-9, 
VEGF, Ang-1 and Ang-2 (Pomye 2001, Brafman 2004, Luo 2004).   
 
 
3.6 IMMUNOHISTOCHEMISTRY 
Study III: Immunohistochemistry was performed at P17 in retinal sections from 
C57BL/6J mice exposed or not exposed for hyperoxia, with antibodies for P2 receptors. 
Visualization was done with a fluorescence microscope. 
 
Study IV: Immunohistochemistry was performed at P17 on cryosections from IL-10 
WT and KO mice exposed to hyperoxia, using antibodies for macrophages/microglia. 
Visualization was done with a fluorescence microscope. 
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3.7 MICROARRAY 
Study III: To study changes in gene expression over time in retinas in normoxia (P12 
and P17) and induced by hyperoxia (P7, P12 and P17) in A2AR WT and KO mice DNA 
microarray was used. RNA samples for each genotype and time point, were analysed 
for quality and concentration by using the Agilent 2100 Bioanalyzer. 100 ng of total 
RNA of each sample was reverse transcribed and amplified into cDNA. The cDNA was 
labeled with a fluorescent dye and hybridized to Gene Chip Mouse Gene 1.0 ST arrays 
(Affymetrix). Nonspecific binding was washed off and the microarray was dried. A 
laser excited the fluorescent dyes producing light detected by a scanner. The scanner 
generated a digital image from the excited microarray. The digital image was further 
processed by specialized software to transform the image of each spot to a numerical 
reading. 
 
 
3.8 GENE ONTOLOGY 
Study III:  Gene Ontology (GO) is a way to use bioinformatics, that is, the creation and 
maintenance of databases to store biological information, to unify the representation of 
genes and gene products across species. The GO project provides a study of defined 
terms representing gene product properties. Three ontologies have been constructed: A. 
Biological processes which refers to a biological objective to which the gene or gene 
product contributes. Example of a biological process is: “cell growth and maintenance” 
or “signal transduction”. B. Molecular function which is defined as the biochemical 
activity of a gene product. Example of a molecular function is: “enzyme” or “ligand”. 
C. Cellular components refers to the place in the cell where a gene product is active. 
Examples of cellular components is: nuclear membrane” or “Golgi apparatus”. Each 
GO term has a specific term name and a definition with cited sources (Ashburner 
2000). 
 
3.8.1 Gene set enrichment analysis (GSEA) 
Gene expression analysis with DNA microarrays that simultaneously measures the 
expression levels of thousands of genes generates huge amounts of data. The challenge 
no longer lies in obtaining gene expression profiles, but rather in interpreting the results 
to gain insights into biological mechanisms. The genes from the microarray experiment 
can be ordered in a ranked list according to their differential expression. A common 
approach involves focusing on a handful of genes at the top and bottom of the list (i.e., 
those genes showing the largest difference) to get proposals of biological information. 
This approach however, has a few major limitations. First no individual gene may meet 
the threshold for statistical significance, because the relevant biological differences are 
modest relative to the noise inherent to the microarray technology. Secondly there can 
be a long list of statistically significant genes without any unifying biological theme. To 
overcome these analytical challenges, the Gene Set Enrichment Analysis (GSEA) is 
developed to evaluate microarray data at the level of gene sets. The gene sets are based 
on prior biological knowledge, e.g., published information about biochemical pathways 
or coexpression in previous experiments. Given an a priori defined set of genes (e.g., 
genes encoding products in a metabolic pathway, located in the same cytogenetic band, 
or sharing the same GO category), the goal of GSEA is to determine whether the 
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members of the gene set are randomly distributed throughout list or primarily found at 
the top or bottom (Subramanian 2005). In Study III we used GSEA for analysis of 
different gene sets in the microarray analysis including: “angiogenesis”, “endothelial 
cells”, apoptosis” and “astrocytes”, however we did not find any significant differences.  
 
 
3.9 STATISTICAL ANALYSIS 
Study I: Student’s two-tailed t test for unpaired data was used to determine whether 
there were significant (p < 0.05) differences in pathologic retinal angiogenesis between 
the MMP-2 KO and WT mice. 
 
Study II: Statistical analysis was performed using one-way ANOVA test after 
logarithmic transformation of the mean nuclear value. A post hoc least significance 
difference (LSD) test was run to establish which means differed. The level of 
significance was set at 0.05 to determine whether there were significant differences in 
pathologic retinal angiogenesis between control, suramin injected and PPADS injected 
mice. 
 
Study III. Student’s two-tailed t-test for unpaired data was used to determine whether 
there were significant differences (P<0.05) concerning A2AR and A2BR mRNA 
expression, area of avascularity and pathologic retinal angiogenesis. In gene-expression 
profile analysis the R statistics software and the Limma package were used for 
microarray data and differential gene expression analysis. The Broad Institute Gene Set 
Enrichment Analysis (GSEA) software was used for analysis of enriched gene ontology 
terms and cell type specific markers. 
 
Study IV: Student’s two-tailed t-test for unpaired data was used to determine whether 
there were significant (P<0.05) differences in pathologic retinal angiogenesis between 
the IL-10 WT and KO mice. Differences in mRNA expression in the retina at P17 
between the IL-10 WT and KO mice were determined by Mann-Whitney U test. P< 
0.05 was considered to be significant. 
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4 RESULTS 
4.1 STUDY I 
We investigated the involvement of MMP-2 in both normal retinal vessel development 
and in OIR. In normal retinal vessel development we found that there was no difference 
concerning the growth of the retinal vessels between WT, and MMP-2 KO mice. In 
both groups the retinal vessels were barely seen around the optic disc at P0. The 
formation of the primary vascular plexus with small branching vessels had a similar 
appearance and reached the ora serrata by P10 in both WT and MMP-2 KO mice. At 
P15, the retinal vasculature had a mature appearance in both groups.  
 
In OIR we found neovascular nuclei inside the ILM in both WT and MMP-2 KO mice. 
However, the amount of neovascular nuclei was significantly higher in the MMP-2 KO 
mice group.  Since the extent of retinal neovascularization is correlated to the degree of 
inner retinal ischemia, retinas from P12 animals were analyzed for differences in 
hyperoxia-induced microvascular closure. P12 is the time-point when mice are 
transferred from the high oxygen chamber to normal environment. However, no 
apparent difference in the central capillary non-perfusion was detected between WT 
and MMP-2 KO mice.  
 
The expression of MMP-2 mRNA was analyzed in the retina at P1 to P19 using in-situ 
hybridization. Expression of MMP-2 mRNA coincided with the formation of the INL 
that appeared around P8. MMP-2 was uniformly distributed.  The expression increased 
gradually until P10 and remained unchanged thereafter. There was no apparent spatial 
or temporal correlation between MMP-2 expression and the development of the 
vascular plexus. The overall distribution of MMP-2 mRNA was similar in retinas from 
OIR and normal mice. This expression was distinct from the expression of VEGF that 
was strongly up-regulated in the INL during OIR.  
 
MMP-2 mRNA expression was also investigated by rt-PCR. The rt-PCR data showed, 
in agreement with the in-situ hybridization results, that exposure to hyperoxia was not 
related to an up-regulation of MMP-2 mRNA expression at any time point. During 
normal retinal vessel development there was a tendency to declining MMP-2 mRNA 
expression. 
 
 
4.2 STUDY II 
The involvement of P2 receptors in OIR was investigated. First the expression of P2X 
and P2Y receptors was analyzed by immunohistochemistry in mice, exposed to 
normoxia, and thereafter in the OIR model. P2X2 receptor expression was mainly 
found in the outer plexiform layer of normoxic mice. In oxygen-treated mice, the 
expression was similarly found in the OPL. In addition, a strong signal was also found 
in the inner layers, particularly the IPL. Immunoreactivity to P2X1 and P2X3 was not 
seen in either normoxic or oxygen-treated animals. In normoxic mice, weak P2Y2 
receptor expression was also seen in the GCL and in the NFL. In mice treated with 
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oxygen, P2Y2 expression showed a similar overall distribution as normoxic mice. The 
signal was, however, strongly up-regulated.  
 
The role of P2 receptors in OIR was further investigated using the P2 receptor 
antagonists, suramin and PPADS. In untreated OIR mice, the mean number of nuclei 
above the ILM was 25.2 ± 4.8. Systemic treatment with a single dose of either suramin 
or PPADS resulted in a dramatic decrease in neovascularization (5.7 ± 4.2 and 2.3 ± 0.5 
nuclei, respectively).  
 
The effect of suramin on P2X2 and P2Y2 receptor expression in oxygen-treated mice 
was further investigated by immunofluorescence. Intraperitoneal injection of suramin at 
P12 was found to down-regulate the P2X2 receptor expression in the IPL, whereas the 
expression in the OPL remained unchanged compared to non-suramin-injected mice. 
By contrast, P2Y2 receptor expression did not show any difference between suramin-
treated or non-treated mice. 
 
 
4.3 STUDY III 
The importance of the A2R in OIR was investigated. First we examined the expression 
of A2AR and A2BR mRNA by rt-PCR during normal vascular development and in OIR. 
At P12 the expression of A2AR mRNA was significantly higher in the control group 
than in the hyperoxia-treated group. In control retinas, A2AR expression thereafter 
declined between P12 and P17. By contrast, in the hyperoxia-treated group, the 
expression of A2AR remained unchanged. At P17, this translated into unaltered A2AR 
expression in the hyperoxia-treated group as compared to the decrease seen in the 
controls. A2BR mRNA expression showed increased expression between P12 and P17 
in retinas from the hyperoxia-treated group whereas the mRNA levels were unaltered in 
control mice. Attempts to confirm and extend the rt-PCR data using 
immunofluorescence failed as the level of specific fluorescence was low and there was 
no discernable difference between retinas from WT and A2AR KO mice.  
 
Thereafter we wanted to investigate the hyperoxia-induced capillary obliteration at P12 
and P17 in WT and A2AR KO mice. The avascular area was assessed on whole-
mounted retinas. The avascular area at P12 was smaller, though not significantly 
different in A2AR KO mice compared to controls. At P17 the avascular area was 
however significantly reduced in the A2AR KO retinas. 
 
We also used the OIR model to estimate the oxygen-induced formation of neovascular 
nuclei in WT and in A2A KO mice. Although retinal neovascularization was evident in 
both WT and A2AR KO mice the number of neovascular nuclei was significantly lower 
in the A2AR KO mice. 
 
To characterize in detail the molecular changes potentially responsible for the observed 
phenotype associated with A2AR deficiency in the retina during the OIR phases (i.e. 
vasoobliteration at P12 and retinal neovascularization at P17) we performed gene 
microarray expression analyses. P12 and P17 normoxic retinas of WT and A2AR KO 
mice and P7, P12 and P17 retinas subjected to hyperoxia were studied. For mice that 
  15 
had been in hyperoxia differences were found in gene expression changes from P7 to 
P12 between WT and A2AR KO mice. When analyzing the most significant differences, 
corresponding to 80 genes, we found that the P12 WT mice differed significantly from 
the P12 A2AR KO mice and also from P7/P17 WT and A2AR KO mice. This difference 
at P12 between WT and A2AR KO mice were not seen in retinas from mice subjected to 
normoxia. There were no connections associated with signal paths or cellular structures 
among the genes.  
 
No difference was found in gene expression between hyperoxic P7 WT and A2AR KO 
mice. Only small differences were seen between WT and A2AR KO mice in normoxia 
and hyperoxia at P17.  
 
In hyperoxic mice at P12 we identified Pttg1 to be expressed more than 10 times higher 
in the A2AR KO mice as compared to WT mice. Rt-PCR confirmed this difference in 
Pttg1 mRNA expression. 
 
 
4.4 STUDY IV 
The involvement of IL-10 in OIR was investigated in WT and in IL-10 KO mice. 
Although pathologic retinal angiogenesis was evident in both WT and IL-10 KO mice 
the number of neovascular nuclei was three times lower in the IL-10 KO mice group.  
 
To examine whether IL-10 mRNA expression was related to OIR we assessed relative 
IL-10 mRNA expression levels by rt-PCR. IL-10 mRNA levels were detectable in 1 out 
of 8 P7 WT mice, in 1 out of 8 P12 mice and in 1 out of 10 P17 mice. In WT mice 
exposed to hyperoxia, IL-10 mRNA levels were detectable in 2 out of 9 mice on P12 
and in 7 out of 10 mice on P17. 
 
By analyzing potential compensatory differences we sought to explain the observed 
effects of IL-10-deficiency in OIR. With rt-PCR mRNA expression of well-known 
angiogenic factors was examined. The relative ratios between MMP-2-, MMP-9-, 
VEGF, Ang-1, and Ang-2 mRNA in relation to GAPDH mRNA levels in IL-10 KO 
mice P17 compared to P17 WT mice were determined. However, no significant 
difference between IL-10 KO and WT mice was found for any of the genes examined.   
 
We also studied the potential differences in the presence of retinal macrophages or 
microglial cells close to neovascular tufts in WT and IL-10 KO mice. However, retinal 
cryosections, P17, from WT mice stained with anti-F4/80 antibodies showed only 
occasional macrophages/microglial cells. No macrophages/microglial cells were 
observed in cryosections from IL-10 KO mice at P17. 
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5 DISCUSSION 
In the eye, formation of new vessels in different diseases is a major cause of vision loss 
and blindness. Several ocular structures can be affected by pathologic vessel growth 
including the cornea, iris, retina and choroid. In the retina, ischemic retinopathies with 
associated pathologic retinal neovascularization, such as ROP, DRP and retinal vein 
occlusions affect millions of people worldwide. 
 
Anti-angiogenic treatment has revolutionized eye-care starting with the management of 
neovascular age-related macular degeneration (using VEGF inhibitors such as 
bevacizumab (Avastin®) and ranibizumab (Lucentis®)(Rosenfeld 2006)). VEGF 
inhibitors have since also been successfully used to manage vascular leakage and 
macular edema in diabetes (Massin 2010) and retinal vein occlusions (Heier 2012) as 
well as pathologic vessel growth in ROP (Mintz-Hittner). In treating neovascular 
conditions with VEGF inhibiors it is however important to be cautious with doses and 
timing to avoid complications like tractional retinal detachment. The OIR model, used 
in the present thesis, is suitable as an experimental model for retinal neovascularization 
in general and for ROP in particular.  
 
In Study I we investigated the role of MMP-2 in normal retinal development and in 
OIR. We found no difference in normal retinal vessel development between MMP-2 
KO and WT mice. At P0 no retinal vessels were seen. By P9 the retinal vessels had 
grown out, radially from the center of the retina around the optic nerve, to the reach the 
ora serrata and at P15 both groups had developed a mature appearance. A similar 
finding has been reported in rats given different MMP antagonists where no effect was 
observed on the normal retinal vascular development as determined by measuring 
vascular areas (Barnett 2007). 
 
In the OIR-model we compared WT and MMP-2 KO mice. We found that the extent of 
neovessels at P17 was significantly higher in the MMP-2 KO mice group as compared 
to WT mice. Surprisingly, MMP-2 acted as an anti-angiogenic factor in our model. 
This is in contrast to previous findings showing regression of pathologic 
neovascularization in MMP-2 KO mice (Ohno-Matsui 2003). The reason for this 
discrepancy is not clear. One explanation could be the difference in the methods for 
quantifying retinal neovascularization. Whereas we have used a protocol counting the 
extraretinal neovascular nuclei on serial sections stained with haematoxylin and eosin 
(Smith 1994), Ohno-Matsui instead stained the retinal endothelial cells with the lectin 
Griffona simplicifolia and then measured the total stained area thereby including both 
intra- and extraretinal vessels. A later work though has also shown reduction in 
preretinal neovascularization in MMP-2 KO mice (Barnett 2007). Maybe, differences 
in the susceptibility to OIR are related to genetic variations resulting from differences 
in genome manipulation. The MMP-2 KO mice in our study contained the commonly 
used 129 strain known to have increased susceptibility to neovascularization (Rohan 
2000). 
 
 
In Study II we found expression of P2 receptors both in normal retinal development 
and in OIR. In normoxia, P2X2 receptor expression was detected in the OPL. Mice 
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exposed to hyperoxia showed P2X2 receptor expression in the OPL but there was also 
strong P2X2 expression in the inner retinal layers, especially in the IPL. Earlier work 
on P2X2 expression in adult mice and rats noted P2X2 receptor expression in the inner 
retinal layers, including the GCL, the IPL, and the INL (Greenwood 1997, Kaneda 
2004, Puthussery 2006). The adult adult pattern of P2X2 expression in mice and rats is 
thus consistent with the P2X2 receptor expression in young mice after exposure to 
hyperoxia. This difference in P2X2 receptor expression in our young mice and earlier 
studies in adult mice and rats is not obvious but probably reflects a developmental 
change. 
 
In normoxia we found P2Y2 receptor expression in the GCL and NFL. This pattern 
was unchanged in mice exposed to hyperoxia.  This finding is consistent with earlier 
work where P2Y2 immunostaining was mainly found in the innermost retinal layers in 
adult rat and pig retina (Fries 2004, Iandiev 2006). 
 
Furthermore we found that oxygen treatment induced P2X2 receptor expression in the 
IPL whereas P2Y2 receptor expression was augmented in the GCL and NFL. This is 
also consistent with earlier findings showing up-regulation of P2X2 receptors by 
hypoxia in cultures from the hippocampus (Cavaliere 2003). Mitotic activation induced 
by hypoxia in retinal microglia cells has been shown to coincide with P2Y2 receptor 
expression (Morigiwa 2002). Moreover, the mitotic activity was suppressed by the P2 
antagonist suramin.  
 
We found that the P2 antagonists suramin and PPADS both reduced retinal 
neovascularization. Suramin and PPADS both block P2X2 signalling but are only weak 
P2Y2 antagonists (Lambrecht 2002). In addition to its P2 antagonistic effects, suramin 
also inhibits angiogenesis by interfering with VEGF and fibroblast growth factor-2 
(Waltenberger 1996, Kathir 2006). Unlike suramin, PPADS seems to be a much more 
specific P2 antagonist with minimal effects on unrelated proteins (Lambrecht 2002). 
We cannot exclude that the effects of the two P2 antagonists, suramin and PPADS, on 
retinal neovascularization in the OIR model are, at least in part, due to inhibition of 
non-P2 proteins. However, the fact that we observed similar inhibition with two 
unrelated antagonists argues against this. This conclusion is further supported by our 
observation that suramin down-regulates P2X2 receptor expression in the IPL in OIR. 
Moreover, the fact that expression of P2X2 receptors in the IPL was not found in 
normal mice but only in OIR is interesting and suggests that P2X2 receptors in the IPL 
may be directly involved in the development of neovascularization during OIR. 
 
 
In Study III we showed that A2AR KO mice have less pathologic neovascularization at 
P17 compared to WT indicating pro-angiogenic properties of the A2AR in this model 
supporting earlier studies (Adair 2005). The most striking result however was the 
finding that the avascular zone is smaller at P12 in A2AR KO mice compared to WT 
mice. Differences at P12 were also seen in the gene expression profiling experiment 
where P12 WT mice differed considerably from P12 A2AR KO mice and from all other 
time-points. The smaller avascular zone at P12 in the A2AR KO mice could be the result 
of enhanced vascularization or the result of regressed apoptosis during the hyperoxic 
phase (ie. P7 to P12). However, gene ontology analysis of gene expression profile data 
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from P7 to P12 showed no evidence of augmented angiogenesis or regressed apoptosis. 
Another explanation for the smaller avascular zone at P12 in the A2A KO mice could 
be that the astrocytes, normally functioning as template for the growing retinal vessels, 
survived to a greater extent during the hyperoxic phase in our model. Retinal astrocytes 
play a critical role during normal retinal vascular development by expressing VEGF 
and thereby initiating endothelial cell proliferation (Stone 1995, Provis 1997, Stalmans, 
2002). It is likely that astrocytes also play an important role in promoting normal 
revascularization during ischemic injury (Chan-Ling 1992). It has also been shown that 
maintaining retinal astrocytes normalizes revascularization and prevents vascular 
pathology associated with oxygen-induced retinopathy (Dorrell 2010). Our gene 
expression profile analysis, however, could not confirm that the astrocytes (or any other 
nerve cells) were up-regulated. 
 
 
In Study IV the role of IL-10 in the OIR model was studied. We found that IL-10 KO 
mice have significantly less neovascular nuclei compared to WT mice. Retinal IL-10 
mRNA was also up-regulated in OIR in P17 mice. This indicates that IL-10 has pro-
angiogenic properties in OIR. Using rt-PCR we further analyzed whether any other 
known angiogenic factors, including MMP-2, MMP-9, VEGF or Ang-1 or Ang-2 could 
compensate for the loss of IL-10. However, we found no difference between the WT 
mice and the IL-10 KO mice. Overall, our finding that IL-10 having pro-angiogenic 
properties is consistent with a previous study showing that IL-10 has pro-angiogenic 
properties in OIR. This study further found that macrophages from WT mice express 
higher levels of VEGF mRNA compared to macrophages from IL-10 deficient mice 
(Dace 2008). During pathologic retinal neovascularization in OIR, macrophages have 
been seen in proximity to the neovascular tufts (Yoshida 2003, Shen 2007). However, 
in another study it was shown that vitreal macrophages appear to promote aberrant 
angiogenesis through migration and association with neovascular tufts. This lead the 
authors to suggest that the contributions of vitreal macrophages may be marginal 
because only very few macrophages are present in the vitreous. Instead it was 
speculated that resident microglia could be the main source of the neovascular-
associated macrophages (Kataoka 2011). In the present study we looked for retinal 
macrophages/microglia in cryosections from both WT and IL-10 KO mice at P17. 
However, we only found occasional F4/80 positive cells in cryosections from WT mice 
and failed to detect any macrophages /microglia in the IL-10 KO mice. The explanation 
for this lack of macrophages/microglia in our model is unclear.  Further studies are 
needed to define both the importance of IL-10 and of microglia/macrophages in OIR. 
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6 CONCLUSIONS 
Retinal neovascularization is a global health problem in retinal ischemic diseases such 
as ROP, DRP and retinal vein occlusion. If the retinal complications are not properly 
managed they frequently lead to severe vision loss and ultimately blindness. 
The OIR model is currently the only experimental model for retinal neovascularization. 
Although there are ischemic models in other species including rat, cat, dog and 
zebrafish (Kremer 1987, Ricci 1990, McLeod 1996, Zhang 2000, Cao 2008) the murine 
OIR (Smith 1994) is the most commonly used model allowing reproducibility, low-cost 
breeding and the use of transgenic techniques including KO mice. 
  
Common to all ischemic retinopathies is the development of new, irregularly growing, 
blood vessels. It should be pointed out though that the mice used in the OIR model are 
young and healthy and that the origin of the ischemic retinopathy is secondary to 
hyperoxic exposure. In contrast, clinical DRP or retinal vein occlusion is instead a 
consequence of pathologic vascular function. 
 
The work in this thesis has focused on different aspects of retinal angiogenesis and 
retinal vascular development. The presented studies have in several ways expanded our 
understanding of the molecular cascade that leads to ocular neovascularization and has 
revealed some potential treatment strategies for neovascular retinopathies. In the first 
study, MMP-2 surprisingly showed anti-angiogenic properties. Previous and later 
studies have instead suggested that MMP-2 has pro-angiogenic properties during 
pathologic retinal neovascularization (Ohno-Matsui 2003, Barnett 2007). Further 
studies are thus necessary to establish which, or what group of MMPs, are responsible 
for the pathologic growth of retinal vessels and to identify the possible presence and 
extent of redundancy. In the second study, we found P2 receptors to be involved in the 
pathologic retinal vessel growth, which has not been described before. This opens a 
new field for research in exploring possible treatment strategies for neovascular 
retinopathies. In the third study the A2AR was found to act in a pro-angiogenic manner, 
exacerbating the initial vasoobliterative phase of ROP suggesting a therapeutic 
potential for A2AR inhibition. Finally, in the fourth study we show that IL-10 also has 
pro-angiogenic properties. However we did not find any evidence of an inflammatory 
reaction, making further studies necessary to establish the role of IL-10 in retinal 
angiogenisis.  
 
With the increasing number of key molecules revealed in pathologic vessel growth 
multiple corresponding drug targets are identified. Suggested by the present thesis, the 
best treatment strategy is probably to target different steps in the angiogenic cascade 
such the MMPs, purinergic signaling or inflammation. Continued research in sorting 
out these complex connections is important.  
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7 SVENSK SAMMANFATTNING 
Nybildning av blodkärl sker normalt under fosterutvecklingen men även i vuxen ålder 
vid sårläkning, under menstruationscykeln och vid skador orsakade av syrebrist, som 
efter hjärtinfarkt. Det förekommer även sjuklig, patologisk, nybildning av blodkärl vid 
tumörtillväxt och vid de sjukdomar i ögat som är orsakade av syrebrist i ögats näthinna, 
retina.  
 
Syrebrist i näthinnan kan ha olika orsak. Prematuritetsretinopati (ROP) förekommer 
hos barn som föds för tidigt. I den omogna, ofullständigt kärlförsedda, näthinnan 
uppstår syrebrist vilket medverkar till frisättande av kärlstimulerande faktorer bland 
annat vascular endothelial growth factor (VEGF). Detta medför att näthinnans blodkärl 
börjar växa kraftigt och okontrollerat vilket kan orsaka blödningar, ärrläkning och 
näthinneavlossning. Trots laserbehandling och eventuell operation vid avancerade 
stadier av sjukdomen kvarstår ofta kraftig synnedsättning. Hos vuxna är syrebrist i 
näthinnan vanligen orsakat av ögonförändringar vid diabetes eller efter kärlocklusion. 
Näthinnans blodkärl är då ställvis tilltäppta och kan inte leverera tillräckligt med 
syrerikt blod varför syrebrist uppstår. Detta leder, på liknande sätt som vid ROP, till 
frisättning av tillväxtfaktorer varpå okontrollerad, patologisk, kärlnybildning sker. 
 
De aktuella studierna har syftat till att vidga vår förståelse för uppkomst av patologisk 
kärlnybildning i näthinnan på en molekylär och cellulär nivå. Den musmodell för 
patologisk kärlnybildning, oxygen-induced retinopathy (OIR), som använts innebär att 
sju dagar gamla möss (vars ögon mycket liknar ögat hos ett för tidigt fött barn) placeras 
i kuvös med hög syrgashalt (75 % O2) under fem dagar. När musen på 12:e 
levnadsdagen flyttas från kuvösen till vanlig rumsluft (20 % O2) uppstår syrebrist i 
näthinnan och därmed frisättning av kärlstimulerande faktorer vilket leder till 
okontrollerad kärltillväxt. 
 
I de olika delarbetena har vi studerat molekyler som på olika sätt griper in i den kaskad 
av biokemiska reaktioner som leder fram till kärlnybildning. Vi har använt genetiskt 
modifierade möss som saknar funktionella gener (knock-out möss (KO)) för enzymet 
matrix metalloproteinase-2 (MMP-2), den syrekänsliga adenosine A2A receptorn 
(A2AR) eller den inflammations reglerande interleukin-10 (IL-10). Med farmkologiska 
metoder har syrekänsliga purinerga receptorer studerats. För studierna har olika 
molekylära, immunohistokemiska samt histologiska metoder använts. 
 
I den första studien noterades att MMP-2, tillhörande en familj av enzymer viktiga för 
nedbrytning av vävnadens extracellulärmatrix och blodkärlens basalmembran, inte var 
involverad i näthinnans normala kärlutveckling. Vid OIR sågs däremot en ökad retinal 
kärlnybildning hos MMP-2 KO mössen, talande för att MMP-2 här hade en 
kärlhämmande effekt. 
  
I den andra studien fann vi att uttrycket i näthinnan av P2X2 och P2Y2 ökade vid 
exponering för hög syrgashalt. Syrgasorsakad kärlnybildning i OIR modellen 
hämmades kraftigt av två farmakologiska P2 receptor antagonister; suramin och 
PPADS, vilket även åtföljdes av en minskning av mängden P2X2 receptor. 
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Sammantaget talar resultaten för att P2 receptorer har en viktig betydelse för 
uppkomsten av retinal kärlnybildning samt att läkemedel som blockerar P2 receptorer 
kan minska skadlig kärlnybildning i näthinnan.  
 
I den tredje studien fann vi att en hög syrgashalt minskade A2AR, medan den minskning 
av A2AR mellan levnadsdag 12 och dag 17 som sågs hos kontrollerna saknades hos de 
möss som vistats i hög syrgashalt. I OIR modellen sågs hos A2AR KO möss en 
minskning i både inledande kärlbortfall och senare retinal kärlnybildning. Gen 
expressions analys med microarray av näthinna från möss som exponerats för hög 
syrgashalt visade att 12 dagars kontroll möss skiljde sig avsevärt från 12 dagars A2AR 
KO möss samt från alla andra tidpunkter. Tillsammans talar fynden för att A2AR 
huvudsakligen verkar genom att öka den inledande fasen av kärlbortfall vid OIR. Som 
en konsekvens av detta skulle hämning av A2AR kunna vara en möjlig behandling vid 
ROP. 
 
I den fjärde studien fann vi att IL-10 stimulerar retinal kärlnybildning i OIR modellen. 
Någon direkt koppling mellan inflammation och IL-10 effekten kunde inte påvisas. 
 
Sammanfattningsvis har vi med de aktuella studierna på olika sätt studerat och klargjort 
olika mekanismer vid kärlnybildning i näthinnan. Två möjliga behandlingsstrategier 
vid patologisk kärlnybildning har identifierats, farmakolgisk hämning av dels P2 
receptor och dels adenosin A2A receptor signalering. 
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